Skip to main
CNTX

CNTX Stock Forecast & Price Target

CNTX Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 80%
Buy 20%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Context Therapeutics Inc is demonstrating a strong trajectory in its clinical development, particularly with the promising early data from its CTIM-76 program, which highlights favorable safety profiles and initial efficacy in heavily pre-treated patients. The company's robust financial positioning, with an extended cash runway into 2027, supports its ongoing development efforts across multiple assets, enhancing its potential for near-term value catalysts. Furthermore, the unique mechanism of CTIM-76, targeting CLDN6 with high potency, positions Context Therapeutics favorably against competitors, with the potential to attract partnerships and generate investor interest ahead of more traditional data releases.

Bears say

Context Therapeutics Inc. demonstrated a significant reduction in research and development expenses, with a decline from $16.8 million in Q3 2024 to $8.7 million in Q3 2025, driven by the absence of prior in-process charges. Despite this reduction, the company reported a net loss of $9.7 million in Q3 2025, down from $17.5 million the previous year, indicating ongoing financial challenges. Furthermore, the company faces several risks such as the need for approximately $250 million in additional financing by 2041, potential safety and efficacy uncertainties in its clinical programs, and risks of delisting due to inadequate stock performance and low trading volume.

CNTX has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 80% of analysts recommend a Strong Buy, 20% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Context Therapeutics LLC and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Context Therapeutics LLC (CNTX) Forecast

Analysts have given CNTX a Strong Buy based on their latest research and market trends.

According to 5 analysts, CNTX has a Strong Buy consensus rating as of Mar 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Context Therapeutics LLC (CNTX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.